ROBERTO HERNANDO: Open Payments
NPI 1811985708 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,284 in 107 payments from 15 companies in 2025. Trend: 2023 $1,805 · 2024 $2,390 · 2025 $2,284
Food & beverage: $2,175Education: $109
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 13 | $318 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $264 |
| Janssen Pharmaceuticals, Inc | 14 | $254 |
| Neurocrine BioSciences, Inc. | 11 | $237 |
| Alkermes, Inc. | 12 | $223 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $201 |
| Otsuka America Pharmaceutical, Inc. | 10 | $193 |
| Almatica Pharma LLC | 8 | $183 |
| E.R. Squibb & Sons, L.L.C. | 5 | $114 |
| Lundbeck LLC | 4 | $104 |
Products named: CAPLYTA, INGREZZA, REXULTI, INVEGA SUSTENNA, ARISTADA, TRINTELLIX, LOREEV XR, AUSTEDO XR.
Industry payments across FL — which companies pay providers there.
